Table S5. Outcomes for primary and secondary endpoints. Data reported as fractions where number followed-up was given.
| Author, year of publication | Grouping | Patients (n) | 30 day/in-hospital mortality (n) | Aortic related death inc f/u (n) | Paraparesis, paraplegia | Secondary intervention (TEVAR or surgery, n) | Dissection (n) | Rupture (n) | IMH regression (n) | Complete aortic remodelling (n) |
|---|---|---|---|---|---|---|---|---|---|---|
| Bischoff, 2016 | TEVAR | 28 | 1 | 1/27 | 2 (pre-existing) | 6 | 3 | 20/27 | 7/27 | |
| MM | 13 | 0 | 0/12 | 0 | 0 | 9/12 | 3/12 | |||
| Felisaz, 2015 | MM | 10 | 0 | 0 | 0 | 5 | 4/4 | |||
| TEVAR | 5 | 0 | 0 | 0 | 3 | 8/10 | 8/10 | |||
| Li, 2010 | TEVAR | 33 | 0 | 0 | 0 | 0 | 0 | 33/33 | ||
| MM | 23 | 1 | 2 | 4 | 3 | 2 | 17/17 | |||
| Liu, 2013 | MM | 7 | 0 | 0 | 0 | 6 | ||||
| TEVAR | 4 | 0 | 0 | 0 | 4 | |||||
| Piffaretti, 2018 | MM | 19 | 0 | 2 | 1 | 9 | 3 | 1 | ||
| TEVAR | 22 | 0 | 1 | 1 SCI | 1 | 1 | 0 | |||
| Schoenhoff, 2017 | MM^ | 25 | 0 | 1 | 7 | 2 | 13 | 13 | ||
| TEVAR^ | 17 | 1 | 2 | 0 | 0 | |||||
| Wu, 2016 | MM | 34 | 0 | 5 | 1 | 2 | 22 | |||
| TEVAR | 14 | 0 | 1 | 0 | 0 | 13 | ||||
| Ye, 2017 | TEVAR | 34 | 0 | 0 | 1 temporary paraparesis | 0 | 0 | 0 | 39/39 | 32/39 |
| MM | 31 | 1 | 4 | 5 | 5 | 4 | 10/26 | 4/26 | ||
| Zhang, 2011 | MM | 4 | 0 | 0 | ||||||
| TEVAR | 4 | 0 | 0 |
TEVAR, thoracic endovascular aortic repair; ^, patients were grouped according to the treatment they received in the acute phase for this study. MM, medical management; inc f/u, including at follow-up; IMH, intramural hematoma.